KYMR Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natu…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | ||
 Can KT-621 Mark a Turning Point for Kymera Therapeutics? KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027. | ||
Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says Kymera Therapeutics' (KYMR) KT-621 could validate its "oral Dupixent" potential, but with a roughly | ||
 Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript Enrollment completed six months early; $1.5B cash runway into 2029. | ||
Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says Nurix Therapeutics' (NRIX) STAT6 degrader NX-3911 is likely to receive increased recognition after a | ||
 KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end. | ||
 Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR) Kymera Therapeutics, Inc. has reported past second-quarter 2026 results showing a reduced net loss of US$61.21 million and lower basic and diluted loss per share of US$0.62, while also completing Phase 2b enrollment for its KT-621 atopic dermatitis trial around six months ahead of schedule and maintaining a cash balance of about US$1.50 billion. Together with the appointment of experienced immunology developer Dr. Terence Rooney as Chief Medical Officer, these clinical, financial, and... | ||
 Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary Moby summary of Kymera Therapeutics, Inc.'s Q2 2026 earnings call | ||
 Kymera Therapeutics Q2 Earnings Call Highlights Kymera Therapeutics (NASDAQ:KYMR) said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by the end of 2026 and potentially begin Phase 3 development around mid-2027. Chief Executive Officer | ||
 Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of +3.13% and +67.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls | ||
 Here Are Wednesday’s Top Wall Street Analyst Research Calls: Bloom Energy, Dave, Fiverr, Humana, Las Vegas Sands, Lemonade, Procter & Gamble, SK hynix, Wix.com, and More Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise, and a brutal semiconductor selloff forced some major rating reversals across insurance, gaming, tech, and energy stocks. | ||
 Is Kymera Therapeutics Poised for a Breakthrough With KT-621? Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis data closer as it expands its protein degrader pipeline. | ||
American Express, Biogen upgraded: Wall Street's top analyst calls American Express, Biogen upgraded: Wall Street's top analyst calls | ||